Position Statements

A Statement of Solidarity

ASGCT Board of Directors | June 07, 2020

The American Society of Gene & Cell Therapy is the primary professional organization for the development of genetic and cellular therapies to treat human disease. As our mission has always been to improve the human condition, we cannot remain immobile in the face of disturbing injustice perpetuating within our country and society.

Position Statements
Read Full Story

ASGCT Statement on Germline Gene Editing Practices

ASGCT Executive Committee | November 26, 2018

The American Society of Gene & Cell Therapy (ASGCT) considers it wholly unacceptable to use germline gene editing and the implantation of gene-edited embryos to achieve a pregnancy without extensive research into the safety, efficacy, and legality of such applications. Any announcements of, or claims to have begun, such studies in germline gene editing are compromised, both ethically and scientifically.

Position Statements
Read Full Story

Image background: Rita Elena Serda, Duncan Comprehensive Cancer Center at Baylor College of Medicine, National Cancer Institute, National Institutes of Health

ASGCT Supports NIH/RAC Recommendation

ASGCT Staff | August 30, 2018

While the RAC serves a valuable role as an essential public forum for science, safety, and ethics, the current requirements for gene therapies have proven redundant.

Advocacy  |  Policy Updates  |  Position Statements
Read Full Story

ASGCT Releases White Paper Addressing the Value of Gene Therapy

ASGCT Staff | May 11, 2018

The American Society of Gene & Cell Therapy has issued a white paper addressing the value of current and future gene therapies approved for clinical use in the United States.

Position Statements  |  White Paper
Read Full Story

ASGCT Submits Comments on FDA Draft Guidance on Regenerative Medicine Expedited Programs

ASGCT Staff | February 19, 2018

ASGCT expressed appreciation for guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions," especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

Policy Updates  |  Position Statements
Read Full Story

Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.